Positron emission tomography (PET) using novel radiotracers that target prostate-specific membrane antigen (PSMA) has demonstrated increased sensitivity and specificity for detecting micrometastatic disease at both initial staging and at BCR, especially in patients with lower PSA values [11,12,13]. Here, FOLH1 is linked to glycogen storage disease VI.